# ARCHITECT Nancomycin

# 510(k) Summary (Summary of Safety and Effectiveness

This summary of the 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

Theassigd 1ou K073036

Preparation Date: 19th July 2007

# Applicant Name:

Mr. Joan Guixer   
Director of Quality Assurance and Regulatory Affairs Biokit S.A.   
Llica d'Amunt   
Barcelona, Spain 08186   
Device Name:   
Reagents   
Classification Name: vancomycin test system   
Trade Name: ARCHITECT iVancomycin Immunoassay   
Common Name: vancomycin test   
Governing Regulation: 862.3950   
Device Classification: Class II   
Classification Panel: Toxicology   
Product Code: LEH   
Calibrators: Classification Name: Calibrator, drug specific   
Trade Name: ARCHITECT iVancomycin Calibrators (A-F)   
Common Name: Calibrator   
Governing Regulation: 862.3200   
Device Classification: Class II   
Classification Panel: Toxicology   
Product Code: DLJ

# Legally marketed device to which equivalency is claimed:

AxSYM Vancomycin II (K955851)

# Intended Use of Device:

The ARCHITECT iVancomycin assay is an in vitro chemiluminescent microparticle immunoassay (CMIA) for the quantitative measurement of vancomycin in human serum or plasma on the ARCHITECT i System with STAT protocol capability. The ARCHITECT iVancomycin assay is used in the diagnosis and treatment of vancomycin overdose and in monitoring levels of vancomycin to help ensure appropriate therapy.

# Description of Device:

The ARCHITECT iVancomycin assay is a one-step STAT immunoassay for the quantitative measurement of vancomycin in human serum or plasma using CMIA technology, with flexible assay protocols, referred to as Chemiflex.

Sample, anti-vancomycin coated paramagnetic microparticles, and vancomycin acridinium-labeled conjugate are combined to create a reaction mixture. The antivancomycin coated microparticles bind to vancomycin present in the sample and to the vancomycin acridinium-labeled conjugate. After washing, pre-trigger and trigger solutions are added to the reaction mixture. The resulting chemiluminescent reaction is measured as relative light units (RLUs). An indirect relationship exists between the amount of vancomycin in the sample and the RLUs detected by the ARCHITECT $i$ System optics.

# Comparison of Technological Characteristics:

The ARCHITECT iVancomycin assay is a chemiluminescent microparticle immunoassay (CMIA) method for the quantitative measurement of vancomycin in human serum and plasma. The AxSYMÂ® Vancomycin II assay utilizes fluorescence polarization immunoassay (FPIA) technology for the measurement of vancomycin in serum or plasma.

# Summary of Non-Clinical Performance:

The ARCHITECT iVancomycin assay is substantially equivalent to the AxSYM Vancomycin II assay in terms of precision, linearity and interferences as demonstrated in non-clinical performance data in this 510(k) submission.

# Summary of Clinical Performance:

The ARCHITECT iVancomycin demonstrated substantially equivalent performance to the AxSYM Vancomycin II with a correlation coefficient of 0.996.

# MAR 19 2008

Biokit, S.A.   
Can Male S/N   
c/o Mr. Joan Guixer   
Director of Quality Assurance & Regulatory Affairs Llica d'Amunt   
Barcelona, Spain 08186

Re: k072036 Trade Name: ARCHITECT iVancomycin Reagents and ARCHITECT iVancomycin Calibrators (A-F) Regulation Name: 21 CFR 862.3950 Regulatory Class: Class II Product Codes: LEH, DLJ Dated: March 06, 2008 Received: March 17, 2008

Dear Mr. Guixer:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section $5 1 0 ( \mathrm { k } )$ premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0490. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address at   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Jean M.COopes, M.S. D.V.M. Jean M. Cooper, M.S., D.V.M.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and   
Radiological Health

# Indication for Use

510(k) Number (if known):

Device Name: ARCHITECT iVancomycin Reagents and ARCHITECT iVancomycin Calibrators (A-F).

Indication For Use:

# Reagents

The ARCHITECT iVancomycin assay is an in vitro chemiluminescent microparticle immunoassay (CMIA) for the quantitative measurement of vancomycin in human serum or plasma on the ARCHITECT i System with STAT protocol capability. The ARCHITECT iVancomycin assay is used in the diagnosis and treatment of vancomycin overdose and in monitoring levels of vancomycin to help ensure appropriate therapy.

# Calibrators

The ARCHITECT iVancomycin Calibrators are for the calibration of the ARCHITECT i System with STAT protocol capability when used for the quantitative determination of vancomycin in human serum or plasma.

For in vitro diagnostic use.

And/Or

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/50bf6ee1383cd6d6f5235e8382c7fb7fa067df1a753e4b58e7a9cd6148cd4bcb.jpg)

Division Sign-Off -- Office of In Vitro Diagnostic Device Evaluation and Safety